Aldeyra Therapeutics Inc
Geschlossen
1.53 6.99
Übersicht
Veränderung der Aktienkurses
24h
Min
1.43
Max
1.56
Einkommen | -8.9B -8.9B |
|---|---|
EPS | -0.16 |
Angestellte | 7 |
EBITDA | -2.5M -5.5M |
Nächstes Ergebnis | 3. Nov. 2026 |
|---|
Marktkapitalisierung | -1.2M 91M |
|---|---|
Vorheriger Eröffnungskurs | -5.46 |
Vorheriger Schlusskurs | 1.53 |
Aldeyra Therapeutics Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Aldeyra Therapeutics Inc Prognose
Finanzen
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$
Über Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.